Cassava Sciences (SAVA) Upgraded to Strong Buy by sfbanc
The Californer/10206797

WEST HOLLYWOOD, Calif. - Californer -- Simufilam is a leading candidate to become the first effective treatment for Alzheimer's Disease. In an analysis by sfbanc financial, Cassava Sciences, Inc. (SAVA) was upgraded as a Strong Buy, from 8/10 to 9.5/10.

The drug in development purportedly works by retiring the proper conformation of filamin A, a molecule involved in the cascade of Alzheimer's disease. Open-label results are showing effectiveness in 84% of subjects treated. These promising results, along with recent insider buying, has led the sfbanc community to upgrade the stock.

More on The Californer

• Independent Financial Group Expands East Coast Recruiting Reach with the Hiring of Former Osaic Executive Bruce Levitus
• Talbot Law Group, P.C. Announces Super Lawyers® 2025 Honors for Matthew B. Talbot and Mark E. Miyasaki
• Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
• California: Governor Newsom challenges President Trump to adopt model executive order to help 'Make America Rake Again'
• Long Beach Airport Named Number Two Airport in Nation by The Washington Post

Additional results from the open label trial are expected by the end of this year. Call volume shows optimism for the results of the Cognitive Maintenance Study (CMS) in late 2023. This trial will include 100 subjects randomized to switch from active drug to placebo. Simufilam is currently in two randomized placebo-controlled Phase 3 trials.

sfbanc is a financial community that provides analysis and discussion of available public information in the finance sector. https://sfbanc.com